



16 June 2023

## Shareholder Update



### **Myopharm™ strengthens licensing pipeline with BIO-E Australia by licensing WHOLESIM product®**

- **Myopharm completes an additional licensing agreement with BIO-E for the WHOLESIM® brand.**
- **Expanding weight loss product sales into Greater China.**
- **Licence is for three years minimum.**

Myopharm Limited is pleased to announce that it has completed an additional licence agreement with BIO-E Australia for WHOLESIM.

WHOLESIM is a unique, complete, very low calorific diet (VLCD) marketed as a weight loss product. It contains natural ingredients. Ingredients that help boost metabolism, suppress appetite, and promote fat burning (ketosis) while providing the essential vitamins and minerals that constitute a complete and safe diet.

Myopharm expects the benefit of this licence to be a 10% royalty on all WHOLESIM product sales.

The licence agreement is for Greater China region with a minimum three-year period with a royalty. Myopharm is expected to have WHOLESIM sales in China this quarter.

Myopharm continues to assess and execute upon growth opportunities associated with new product launches in Australian pharmacy and hospital channels and the overseas markets that develop and support global market access and significant growth opportunities. We are preparing for significant activity and growth and look forward to updating Shareholders.

#### **About BIO-E Australia**

BIO-E is a healthcare innovation company based in Victoria, Australia, with 60 staff. They have been highly successful in the Greater China region with online sales, local manufacturing, R&D Innovation, and Marketing. BIO-E source select products backed by review and science with an explicit market need. BIO-E is renowned for its marketing abilities and marketing business plans that drive large volumes through China.

BIO-E are highly experienced formulators that work alongside nutritionists, chemists, PhD scientists and run a number of successful subscription wellness platforms with active member participation and sales. Founder Andy Tu, started cross-border e-commerce in 2013 and became Australia's Top 3 distributor for Vitamins, Minerals, Herbs, and Supplements (VMHS) products, representing leading brands such as Swisse, Blackmores, Lifespace etc. Together with his wife Julia, they co-founded BIO- E in 2015, which became one of T Mall's "RMB100m annual sales" brands in 2020.

Regards

**Karinza Phoenix**

Myopharm Limited

Executive Chair & Chief Executive Officer

[kphoenix@myopharm.com](mailto:kphoenix@myopharm.com)

*Release authorised by the Executive Chair and Chief Executive Officer of Myopharm Limited*

For Investor Enquiries, please get in touch with us at [Investor@myopharm.com](mailto:Investor@myopharm.com)

**About Myopharm**

**Website:** [www.myopharm.com](http://www.myopharm.com)

Myopharm is a diabetes focussed company developing innovative diabetes solutions that delay disease progression and improve quality of life. At Myopharm, our research and development teams develop clinically validated medical, nutritional and pharmaceutical products based on an innovative multitarget approach enabled by leading scientists from a high level of evidence.

Our goal: reduce metabolic diseases that millions of people worldwide are at risk of. We acknowledge that now is the time to act on preventing diabetes through better diet and therapies.

International Diabetes Federation released an alarming growth rate in the prevalence of diabetes, with over 800 million adults worldwide living with diabetes. Closer to home, diabetes is now the fastest-growing chronic condition in Australia.